AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This Phase II study will recruit 40 metastatic non-small cell lung cancer patients who failed
treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune
checkpoint antibody, administered simultaneously or sequentially. All recruited patients will
receive AB-16B5 at a dose of 12 mg/kg once weekly combined with docetaxel at a dose of 75
mg/m2 once every 3 weeks.